Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Etoricoxib→

Etoricoxib Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
202409-33-4
Molecular formula
C18H15ClN2O2S
Molecular weight
358.8 g/mol
Drug class
Selective cyclo-oxygenase-2 (COX-2) inhibitorcoxib NSAID
Mechanism of action
Selectively and dose-dependently inhibits COX-2 within the clinical dose range, reducing prostaglandin synthesis associated with pain and inflammation; it does not inhibit COX-1 at doses up to 150 mg daily in cited clinical pharmacology studies.
Indications / reported uses
  • Symptomatic relief of osteoarthritis and rheumatoid arthritis
  • Ankylosing spondylitis
  • Pain and signs of inflammation associated with acute gouty arthritis
  • Short-term treatment of moderate pain associated with dental surgery; age and dose restrictions are product-specific

Sources: UK SmPC — Etoricoxib 30 mg · UK SmPC — Etoricoxib 120 mg · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Etoricoxib Environmental Risk Assessment (ERA) (the Etoricoxib ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.